
Xencor (XNCR) Stock Forecast & Price Target
Xencor (XNCR) Analyst Ratings
Bulls say
Xencor is a biopharmaceutical company with a promising pipeline of engineered antibodies that target both cancer and autoimmune diseases. With a strong focus on research and development, continued partnership agreements and licensing agreements, and a diverse pipeline of product candidates, Xencor is well-positioned for future success. Furthermore, the company has upcoming clinical data readouts for several of its key programs, which could de-risk potential indications and drive further upside. While clinical and financial risks exist, Xencor has a strong foundation and promising prospects as it continues to advance its innovative therapies.
Bears say
Xencor is a clinical-stage biopharmaceutical company with a single reportable segment focused on discovering and developing engineered antibody therapeutics. Their revenue primarily comes from collaboration and licensing agreements, and they have a diverse pipeline with product candidates targeting cancer and autoimmune diseases. However, with a target dose range not expected to be reached until 2027 and a decision to shift focus and capital away from a low probability Phase 3 study, Xencor's future may be uncertain.
This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.
Xencor (XNCR) Analyst Forecast & Price Prediction
Start investing in Xencor (XNCR)
Order type
Buy in
Order amount
Est. shares
0 shares